BCL2 and ulcerative colitis: The results showed that cycloastragenol treatment improved the induced morphological changes, and in ulcerative colitis rats, this compound significantly reduced expression levels of SphK, MIP-1α, BAX, NF-κB, TNF-α, and active caspase-3, associated with BCL2 and miR-143 overexpression.